SCHEMBL8026096

SCHEMBL8026096

CO/C=C(/Oc1cc(/C(C)=N/O)ccc1C)C(=O)OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.37
MAPT P10636 6/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
POLB P06746 2/20 0.35
ALDH1A1 P00352 5/20 0.34
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34
ACHE P22303 1/20 0.33
CA9 Q16790 3/20 0.32
TAS1R3 Q7RTX0 1/20 0.32
TAS1R1 Q7RTX1 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA4 P22748 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
TMPRSS15 P98073 1/20 0.32
CASP3 P42574 1/20 0.31
GFER P55789 1/20 0.31
SENP8 Q96LD8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21647869 1.00 NOTUM (0.37) NOTUMMAPTSMN1; SMN2POLBALDH1A1
SCHEMBL26418271 1.00 NOTUM (0.37) NOTUMMAPTSMN1; SMN2POLBALDH1A1
SCHEMBL8026099 1.00 NOTUM (0.37) NOTUMMAPTSMN1; SMN2POLBALDH1A1
SCHEMBL21675874 1.00 NOTUM (0.37) NOTUMMAPTSMN1; SMN2POLBALDH1A1
SCHEMBL8026100 0.90 NOTUM (0.39) NOTUMMAPTSMN1; SMN2POLBALDH1A1
SCHEMBL8026643 0.87 NOTUM (0.40) NOTUMMAPTSMN1; SMN2POLBALDH1A1
SCHEMBL8026645 0.87 NOTUM (0.40) NOTUMMAPTSMN1; SMN2POLBALDH1A1
SCHEMBL31433051 0.86 RECQL (0.41) NOTUMMAPTSMN1; SMN2POLBKMT2A
SCHEMBL30168596 0.85 MAPT (0.38) NOTUMMAPTSMN1; SMN2ALDH1A1PPARG
SCHEMBL8020369 0.81 PPARG (0.39) NOTUMMAPTALDH1A1PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240114909-A1 METHOD FOR CONTROLLING SOYBEAN RUST FUNGUS HAVING RESISTANCE AGAINST Qo SITE INHIBITOR SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2024-04-11 US disclosed
US-11849728-B2 Method for controlling soybean rust fungus having resistance against Qo site inhibitor SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-12-26 US disclosed
US-20210307328-A1 METHOD FOR CONTROLLING SOYBEAN RUST FUNGUS HAVING RESISTANCE AGAINST Qo SITE INHIBITOR SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-10-07 US disclosed
EP-3831205-A1 METHOD OF CONTROLLING SOYBEAN RUST FUNGUS THAT IS RESISTANT TO QO INHIBITORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-06-09 EP disclosed
EP-0975587-A1 OXIME ETHER COMPOUNDS, THEIR USE AND INTERMEDIATES FOR PREPARATIONS OF THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2000-02-02 EP disclosed
WO-1998043949-A1 OXIME ETHER COMPOUNDS, THEIR USE AND INTERMEDIATES FOR PREPARATIONS OF THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210307328-A1 METHOD FOR CONTROLLING SOYBEAN RUST FUNGUS HAVING RESISTANCE AGAINST Qo SITE INHIBITOR CYC1, COX5B, SQOR NOTUM 1664/4885MAPT 1345/4885SMN1; SMN2 4317/4885
US-20240114909-A1 METHOD FOR CONTROLLING SOYBEAN RUST FUNGUS HAVING RESISTANCE AGAINST Qo SITE INHIBITOR CYC1, COX5B, MT-CO3 NOTUM 1676/4885MAPT 1341/4885SMN1; SMN2 4316/4885
US-11849728-B2 Method for controlling soybean rust fungus having resistance against Qo site inhibitor CYC1, COX5B, SQOR NOTUM 1664/4885MAPT 1345/4885SMN1; SMN2 4317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.